BioNTech and Genentech Terminate Phase 2 Personalized Cancer Vaccine Trial Due to Survival Imbalance

September 6, 2026

Fierce Biotech USA

Overview

BioNTech and Genentech have cancelled their Phase 2 clinical trial for autogene cevumeran (BNT122), a personalized cancer vaccine targeting colorectal cancer patients, after an independent data safety monitoring committee recommended termination. The decision stemmed from a numerical imbalance in overall survival observed in the vaccine arm. This outcome highlights the significant challenges inherent in developing cancer vaccines as standalone therapies.

In Depth

Background

Personalized cancer vaccines represent a promising frontier in oncology, aiming to stimulate a patient’s immune system to recognize and attack tumor-specific neoantigens. BioNTech, a pioneer in mRNA technology, partnered with Genentech to develop autogene cevumeran (BNT122), an individualized mRNA-based vaccine, for patients with colorectal cancer. This collaboration was designed to leverage cutting-edge immunotherapeutic approaches against solid tumors.

Key Findings

BioNTech and Genentech have discontinued the Phase 2 trial for their personalized cancer vaccine, autogene cevumeran (BNT122).
The trial, which focused on colorectal cancer patients, was halted based on the recommendation of an Independent Data Safety Monitoring Committee (IDSMC).
The committee’s recommendation was prompted by the observation of a numerical imbalance in overall survival (OS) within the vaccine treatment arm.
The specific details of the imbalance were not fully disclosed but suggested potential concerns that led to the early termination.

Significance & Outlook

The cancellation of this Phase 2 trial is a notable setback for the personalized cancer vaccine field, particularly for the approach of utilizing such vaccines as a monotherapy. While the underlying reasons for the survival imbalance are not fully detailed, this event underscores the complex biological challenges in consistently eliciting effective and durable anti-tumor immune responses, especially in advanced solid tumors. Developers may need to increasingly explore combination strategies, where cancer vaccines are paired with other modalities like checkpoint inhibitors, to enhance efficacy and overcome potential resistance mechanisms. This outcome will likely prompt further investigation into patient stratification and biomarker identification to better predict responders and optimize clinical trial design for future personalized immunotherapy initiatives.

Source: https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH62m0UWwjk8JWfnr3qHqI5-jSc2yJXoGUK10k6TcjRKkd3QMR4nvuZHaepnlLjooZZofiJNaoGqvkJ6r92nkF6acXpFkCbZcUmlqaoDPxY_tJvwUR-mXD1mjiM91g1VgtZvehskd7zd6GgxpFKTylNhCm2W6nlZJQFJdQ-GLz3WcVAFu0JpaoTpfPUO0GzDc_1l0RBttZqo2Hg7KToOc-VRl72pGx_sfMlNJy_pdGml-cy7RmocCWTRDfggHU=

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.